Tandem Diabetes Care
TNDM
330 hedge funds and large institutions have $3.63B invested in Tandem Diabetes Care in 2022 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 150 increasing their positions, 109 reducing their positions, and 79 closing their positions.
84% more call options, than puts
Call options by funds: $45.5M | Put options by funds: $24.7M
38% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 109
2.74% more ownership
Funds ownership: 93.2% → 95.94% (+2.7%)
13% less funds holding
Funds holding: 379 → 330 (-49)
47% less capital invested
Capital invested by funds: $6.84B → $3.63B (-$3.21B)
53% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 79
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$104M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$90.2M |
| 3 |
Two Sigma Investments
New York
|
+$39.9M |
| 4 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$38.9M |
| 5 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$33.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$174M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$66.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$55.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$38.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$38.4M |
TNDM Hedge Fund Activity: Q2 2022 in Review
330 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q2 2022, worth a combined $3.63B — down 47% from $6.84B a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of TNDM and 37 opened new positions — a net loss of 42 holders — while 109 trimmed existing stakes and 150 added.
The largest buyer was AllianceBernstein, adding an estimated $104M. The largest seller was Jackson Square Partners, exiting entirely with an estimated $174M sold.
- 330 institutional investors held Tandem Diabetes Care (TNDM) as of Q2 2022, down from 379 in Q1 2022.
- Funds reported $3.63B of Tandem Diabetes Care stock for Q2 2022, down 47% quarter-over-quarter.
- 37 funds opened new Tandem Diabetes Care positions in Q2 2022 and 79 closed out, a net change of -42 holders.
- The largest Tandem Diabetes Care buyer in Q2 2022 was AllianceBernstein, an estimated $104M added.
- The largest Tandem Diabetes Care seller in Q2 2022 was Jackson Square Partners, an estimated $174M sold.
Based on aggregated 13F filings for Q2 2022.